Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ALT-803 + PD-L1.t-haNK cells + Pembrolizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|Nogapendekin alfa|ALT803||ALT-803 (Nogapendekin alfa) is a fusion protein consisting a mutant IL-15 and a soluble IL-15Ra Fc, which activates and converts memory CD8+ T cells to effector immune cells with antitumor activity (PMID: 24404427, PMID: 31338557).|
|PD-L1.t-haNK cells||PD-L1 t-haNK|Allogeneic PD-L1-t-haNK||PD-L1.t-haNK cells are natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets PD-L1, which may induce cell killing in PD-L1-expressing tumor cells resulting in decreased tumor growth (PMID: 32439799).|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04847466||Phase II||ALT-803 + PD-L1.t-haNK cells + Pembrolizumab||Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer||Recruiting||USA||0|